• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

吡唑并[3,4-d]嘧啶前药:从文库合成到在原位胶质母细胞瘤模型中作为潜在抗癌药物的评估

Prodrugs of Pyrazolo[3,4-d]pyrimidines: From Library Synthesis to Evaluation as Potential Anticancer Agents in an Orthotopic Glioblastoma Model.

作者信息

Vignaroli Giulia, Iovenitti Giulia, Zamperini Claudio, Coniglio Federica, Calandro Pierpaolo, Molinari Alessio, Fallacara Anna Lucia, Sartucci Andrea, Calgani Alessia, Colecchia David, Mancini Andrea, Festuccia Claudio, Dreassi Elena, Valoti Massimo, Musumeci Francesca, Chiariello Mario, Angelucci Adriano, Botta Maurizio, Schenone Silvia

机构信息

Dipartimento di Biotecnologie, Chimica e Farmacia, Università degli Studi di Siena , Via Aldo Moro 2, 53100 Siena, Italy.

Lead Discovery Siena S.r.l. , via Vittorio Alfieri 31, Castelnuovo Berardenga, 53019 Siena, Italy.

出版信息

J Med Chem. 2017 Jul 27;60(14):6305-6320. doi: 10.1021/acs.jmedchem.7b00637. Epub 2017 Jul 18.

DOI:10.1021/acs.jmedchem.7b00637
PMID:28650650
Abstract

Pyrazolo[3,4-d]pyrimidines are potent protein kinase inhibitors with promising antitumor activity but suboptimal aqueous solubility, consequently worth being further optimized. Herein, we present the one-pot two-step procedure for the synthesis of a set of pyrazolo[3,4-d]pyrimidine prodrugs (1a-8a and 9a-e) with higher aqueous solubility and enhanced pharmacokinetic and therapeutic properties. ADME studies demonstrated for the most promising prodrugs a better aqueous solubility, a favorable hydrolysis in human and murine serum, and an increased ability to cross cell membranes with respect to the parental drugs, explaining their better 24 h in vitro cytotoxicity against human glioblastoma U87 cell line. Finally, the 4-4a couple of drug/prodrug was also evaluated in vivo, revealing a profitable pharmacokinetic profile of the prodrug associated with a good efficacy. The application of the prodrug approach demonstrated to be a successful strategy for improving aqueous solubility of the parental drugs, determining a positive impact also in their biological efficacy.

摘要

吡唑并[3,4 - d]嘧啶是具有良好抗肿瘤活性的强效蛋白激酶抑制剂,但水溶性欠佳,因此值得进一步优化。在此,我们展示了一种一锅两步法来合成一组具有更高水溶性以及增强的药代动力学和治疗特性的吡唑并[3,4 - d]嘧啶前药(1a - 8a和9a - e)。药物代谢动力学研究表明,对于最有前景的前药而言,相较于母体药物,它们具有更好的水溶性、在人和小鼠血清中更有利的水解作用以及更强的跨细胞膜能力,这解释了它们对人胶质母细胞瘤U87细胞系具有更好的24小时体外细胞毒性。最后,还对4 - 4a这对药物/前药进行了体内评估,结果显示前药具有有益的药代动力学特征且疗效良好。前药方法的应用被证明是提高母体药物水溶性的成功策略,对其生物学疗效也产生了积极影响。

相似文献

1
Prodrugs of Pyrazolo[3,4-d]pyrimidines: From Library Synthesis to Evaluation as Potential Anticancer Agents in an Orthotopic Glioblastoma Model.吡唑并[3,4-d]嘧啶前药:从文库合成到在原位胶质母细胞瘤模型中作为潜在抗癌药物的评估
J Med Chem. 2017 Jul 27;60(14):6305-6320. doi: 10.1021/acs.jmedchem.7b00637. Epub 2017 Jul 18.
2
Si113-prodrugs selectively activated by plasmin against hepatocellular and ovarian carcinoma.丝氨酸蛋白酶 113 前药对肝癌和卵巢癌的选择性激活。
Eur J Med Chem. 2021 Nov 5;223:113653. doi: 10.1016/j.ejmech.2021.113653. Epub 2021 Jun 17.
3
Synthesis, EGFR Inhibition and Anti-cancer Activity of New 3,6-dimethyl-1-phenyl-4-(substituted-methoxy)pyrazolo[3,4-d] pyrimidine Derivatives.新型3,6-二甲基-1-苯基-4-(取代甲氧基)吡唑并[3,4-d]嘧啶衍生物的合成、表皮生长因子受体抑制作用及抗癌活性
Anticancer Agents Med Chem. 2017;17(10):1389-1400. doi: 10.2174/1872211311666170213105004.
4
Tyrosine kinase inhibition effects of novel Pyrazolo[1,5-a]pyrimidines and Pyrido[2,3-d]pyrimidines ligand: Synthesis, biological screening and molecular modeling studies.新型吡唑并[1,5-a]嘧啶和吡啶并[2,3-d]嘧啶配体的酪氨酸激酶抑制作用:合成、生物筛选和分子模拟研究。
Bioorg Chem. 2018 Aug;78:312-323. doi: 10.1016/j.bioorg.2018.03.009. Epub 2018 Mar 26.
5
Discovery of 3-(4-sulfamoylnaphthyl)pyrazolo[1,5-a]pyrimidines as potent and selective ALK2 inhibitors.发现3-(4-氨磺酰基萘基)吡唑并[1,5-a]嘧啶作为强效且选择性的ALK2抑制剂。
Bioorg Med Chem Lett. 2018 Nov 1;28(20):3356-3362. doi: 10.1016/j.bmcl.2018.09.006. Epub 2018 Sep 6.
6
2-Hydroxypropyl-β-cyclodextrin strongly improves water solubility and anti-proliferative activity of pyrazolo[3,4-d]pyrimidines Src-Abl dual inhibitors.2-羟丙基-β-环糊精可显著提高吡唑并[3,4-d]嘧啶类Src-Abl 双重抑制剂的水溶性和抗增殖活性。
Eur J Med Chem. 2010 Dec;45(12):5958-64. doi: 10.1016/j.ejmech.2010.09.062. Epub 2010 Oct 8.
7
Design, synthesis, biological activity, and ADME properties of pyrazolo[3,4-d]pyrimidines active in hypoxic human leukemia cells: a lead optimization study.吡唑并[3,4-d]嘧啶类化合物的设计、合成、活性及在缺氧人白血病细胞中的 ADME 性质:一个先导化合物优化研究。
J Med Chem. 2011 Apr 28;54(8):2610-26. doi: 10.1021/jm1012819. Epub 2011 Mar 28.
8
Incorporation of water-solubilizing groups in pyrazolopyrimidine mTOR inhibitors: discovery of highly potent and selective analogs with improved human microsomal stability.在吡唑并嘧啶 mTOR 抑制剂中引入水溶性基团:发现具有更高人肝微粒体稳定性的高活性和选择性类似物。
Bioorg Med Chem Lett. 2009 Dec 15;19(24):6830-5. doi: 10.1016/j.bmcl.2009.10.096. Epub 2009 Oct 25.
9
Design and synthesis of novel 3-sulfonylpyrazol-4-amino pyrimidines as potent anaplastic lymphoma kinase (ALK) inhibitors.新型3-磺酰基吡唑-4-氨基嘧啶作为强效间变性淋巴瘤激酶(ALK)抑制剂的设计与合成
Bioorg Med Chem Lett. 2016 Apr 15;26(8):1910-8. doi: 10.1016/j.bmcl.2016.03.017. Epub 2016 Mar 7.
10
Synthesis and anti-tumor activities of some new pyridines and pyrazolo[1,5-a]pyrimidines.一些新型吡啶和吡唑并[1,5-a]嘧啶的合成及其抗肿瘤活性
Eur J Med Chem. 2009 Sep;44(9):3519-23. doi: 10.1016/j.ejmech.2009.03.042. Epub 2009 Apr 8.

引用本文的文献

1
Evaluation of Antitumoral Activity in a 3D Cell Model of a Src Inhibitor Prodrug for Glioblastoma Treatment.用于胶质母细胞瘤治疗的Src抑制剂前药在三维细胞模型中的抗肿瘤活性评估。
Pharmaceutics. 2025 May 27;17(6):704. doi: 10.3390/pharmaceutics17060704.
2
Advances in pyrazolo[1,5-]pyrimidines: synthesis and their role as protein kinase inhibitors in cancer treatment.吡唑并[1,5 - ]嘧啶的研究进展:合成及其在癌症治疗中作为蛋白激酶抑制剂的作用
RSC Adv. 2025 Feb 5;15(5):3756-3828. doi: 10.1039/d4ra07556k. eCollection 2025 Jan 29.
3
Small Molecule Tyrosine Kinase Inhibitors (TKIs) for Glioblastoma Treatment.
小分子酪氨酸激酶抑制剂(TKIs)治疗脑胶质瘤。
Int J Mol Sci. 2024 Jan 23;25(3):1398. doi: 10.3390/ijms25031398.
4
Recent Advancements and Strategies for Overcoming the Blood-Brain Barrier Using Albumin-Based Drug Delivery Systems to Treat Brain Cancer, with a Focus on Glioblastoma.利用基于白蛋白的药物递送系统克服血脑屏障治疗脑癌的最新进展与策略,重点关注胶质母细胞瘤
Polymers (Basel). 2023 Oct 2;15(19):3969. doi: 10.3390/polym15193969.
5
Identification and Biological Characterization of the Pyrazolo[3,4-]pyrimidine Derivative SI388 Active as Src Inhibitor.作为Src抑制剂具有活性的吡唑并[3,4-]嘧啶衍生物SI388的鉴定及生物学特性研究
Pharmaceuticals (Basel). 2023 Jul 4;16(7):958. doi: 10.3390/ph16070958.
6
Biological Evaluation and In Vitro Characterization of ADME Profile of In-House Pyrazolo[3,4-]pyrimidines as Dual Tyrosine Kinase Inhibitors Active against Glioblastoma Multiforme.作为对多形性胶质母细胞瘤有效的双重酪氨酸激酶抑制剂的内部吡唑并[3,4 -]嘧啶的ADME特性的生物学评价和体外表征
Pharmaceutics. 2023 Jan 30;15(2):453. doi: 10.3390/pharmaceutics15020453.
7
Autophagy Inhibition Enhances Anti-Glioblastoma Effects of Pyrazolo[3,4-]pyrimidine Tyrosine Kinase Inhibitors.自噬抑制增强吡唑并[3,4 - ]嘧啶酪氨酸激酶抑制剂的抗胶质母细胞瘤作用。
Life (Basel). 2022 Sep 27;12(10):1503. doi: 10.3390/life12101503.
8
Anti-Survival Effect of SI306 and Its Derivatives on Human Glioblastoma Cells.SI306及其衍生物对人胶质母细胞瘤细胞的抗生存作用。
Pharmaceutics. 2022 Jul 1;14(7):1399. doi: 10.3390/pharmaceutics14071399.
9
Challenges and opportunities to penetrate the blood-brain barrier for brain cancer therapy.突破血脑屏障治疗脑癌的挑战与机遇。
Theranostics. 2022 Jun 6;12(10):4734-4752. doi: 10.7150/thno.69682. eCollection 2022.
10
Glioblastoma: Current Status, Emerging Targets, and Recent Advances.胶质母细胞瘤:现状、新兴靶点及最新进展。
J Med Chem. 2022 Jul 14;65(13):8596-8685. doi: 10.1021/acs.jmedchem.1c01946. Epub 2022 Jul 5.